The Study
Neurotransmitter and metabolic effects of interferon-alpha in association with decreased striatal dopamine in a Non-Human primate model of Cytokine-Induced depression
This study looked at monkey brains after giving them a medicine that causes inflammation. It found that when inflammation went up, dopamine (a brain chemical for motivation) went down. But it didn’t prove that inflammation made dopamine drop — it just saw them happen together.
Analysis score
Maximum 72 for a cohort study.
Where the score came from
When the body fights infection, it releases a chemical called interferon-alpha that can cross into the brain and mess with the brain's 'motivation battery' — dopamine.
Where does this study sit?
Reviews of RCTs (Meta-analyses)
Max 100Randomized Trials
Max 90Reviews of Cohort Studies
Max 85Cohort Studies
Max 72Reviews of Case-Control Studies
Max 63Case-Control Studies
Max 58Cross-Sectional & Case Series
Max 50Expert Opinion
Max 513 / 100
Quality score
Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.
Key takeaways
Summary
Based on the study abstract and findings.
- 1Yes — this explains why people with chronic infections or inflammation often feel tired, unmotivated, or depressed, even without being sick anymore.
- 2Monkeys given interferon-alpha had 20–30% less dopamine in key brain areas (p < 0.05), and their brain cells showed more inflammation signals and less energy production.
Score breakdown, methodology, conflicts of interest, evidence analysis & raw study data
Publication
Journal
Brain, behavior, and immunity
Year
2025
Authors
M. Bekhbat, A. Block, Sarah Y. Dickinson, Gregory K. Tharpd, S. Bosinger, J. Felger
Related Content
Claims (6)
Dopamine is a brain chemical that directly enables the experience of motivation, reward, and pleasure when encountering environmental cues.
Chronic interferon-alpha exposure in non-human primates reduces dopamine levels in the nucleus accumbens and putamen without changing the number of dopamine terminals or striatal neurons.
Long-term exposure to interferon-alpha in non-human primates is linked to reduced activity in the brain's mitochondrial energy production systems in the putamen.
In non-human primates, interferon-alpha exposure is linked to a lower ratio of protective to excitatory NMDA receptor subunits in the putamen and lower dopamine levels.
In non-human primates given interferon-alpha, specific changes in gene activity in the putamen region of the brain occur alongside lower dopamine levels, including increased activity in inflammatory and synaptic signaling pathways and decreased activity in energy production and dopamine receptor pathways.
In non-human primates, treatment with interferon-alpha reduces the levels of dopamine receptor D2 and DARPP-32 in the putamen, which are proteins involved in dopamine signaling.
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.